Weighted Average Number of Shares Outstanding, Basic of Fulcrum Therapeutics, Inc. from 2020 to Q3 2025

Taxonomy & unit
us-gaap: shares
Description
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
Summary
Fulcrum Therapeutics, Inc. quarterly/annual Weighted Average Number of Shares Outstanding, Basic history and growth rate from 2020 to Q3 2025.
  • Fulcrum Therapeutics, Inc. Weighted Average Number of Shares Outstanding, Basic for the quarter ending September 30, 2025 was 62.6K shares, a 0.3% increase year-over-year.
  • Fulcrum Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2024 was 62K shares, a 1.1% increase from 2023.
  • Fulcrum Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2023 was 61.3K shares, a 36.3% increase from 2022.
  • Fulcrum Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2022 was 45K shares, a 27.2% increase from 2021.
Weighted Average Number of Shares Outstanding, Basic, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Quarterly Growth (%)
Weighted Average Number of Shares Outstanding, Basic, Annual (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Annual Growth (%)

Fulcrum Therapeutics, Inc. Quarterly Weighted Average Number of Shares Outstanding, Basic (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 62.6K +188 +0.3% Jul 1, 2025 Sep 30, 2025 10-Q 2025-10-29
Q2 2025 62.5K +339 +0.55% Apr 1, 2025 Jun 30, 2025 10-Q 2025-07-29
Q1 2025 62.5K +495 +0.8% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-01
Q4 2024 62K +674 +1.1% Oct 1, 2024 Dec 31, 2024 10-K 2025-02-25
Q3 2024 62.4K +586 +0.95% Jul 1, 2024 Sep 30, 2024 10-Q 2025-10-29
Q2 2024 62.2K +411 +0.67% Apr 1, 2024 Jun 30, 2024 10-Q 2025-07-29
Q1 2024 62K +2.26K +3.79% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-01
Q4 2023 61.3K +16.3K +36.3% Oct 1, 2023 Dec 31, 2023 10-K 2025-02-25
Q3 2023 61.8K +15.6K +33.8% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 61.8K +20.9K +51.1% Apr 1, 2023 Jun 30, 2023 10-Q 2024-07-31
Q1 2023 59.7K +19.1K +46.9% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-13
Q4 2022 45K Oct 1, 2022 Dec 31, 2022 10-K 2024-02-27
Q3 2022 46.2K +9.61K +26.2% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 40.9K +8.25K +25.3% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 40.6K Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q3 2021 36.6K Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 32.6K Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11

Fulcrum Therapeutics, Inc. Annual Weighted Average Number of Shares Outstanding, Basic (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 62K +674 +1.1% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-25
2023 61.3K +16.3K +36.3% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-25
2022 45K +9.63K +27.2% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-27
2021 35.4K +10K +39.5% Jan 1, 2021 Dec 31, 2021 10-K/A 2023-06-26
2020 25.4K Jan 1, 2020 Dec 31, 2020 10-K/A 2023-06-26
* An asterisk sign (*) next to the value indicates that the value is likely invalid.